On 7 April 2017 Ambaw Bellete - Head, US Cancer Commercial
Operations - purchased 2,000 Photocure shares at a price of
NOK 30.13 each.
Ambaw Bellete now holds 2,000 shares and 76,600 options in
Photocure.
This notification is made pursuant to the Norwegian
Securities Trading Act sections 4-2.